OTCMKTS:PDDPF Medexus Pharmaceuticals (PDDPF) Stock Price, News & Analysis $2.14 0.00 (0.00%) As of 08/4/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medexus Pharmaceuticals Stock (OTCMKTS:PDDPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PDDPF alerts:Sign Up Key Stats Today's Range$2.11▼$2.4250-Day Range$2.14▼$2.1452-Week Range$1.70▼$3.99Volume39,966 shsAverage Volume4,355 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMedexus Pharmaceuticals, Inc. operates as a pharmaceutical company. It provide healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company products include Rasuvo, Metoject and Rupall. Medexus was founded by Sylvain Chretien in January 2008 and is headquartered in Verdun, Canada.Read More… Receive PDDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PDDPF Stock News HeadlinesPositive Growth Outlook for Medexus Pharmaceuticals Inc. Amid Strategic Expansion and Stable PerformanceFebruary 9, 2025 | tipranks.comStifel cuts Medexus Pharma stock rating to Hold, target to C$3.45February 7, 2025 | msn.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 10, 2025 | Porter & Company (Ad)Medexus targets $100M annual revenue for GRAFAPEX within 5 years post-launchFebruary 6, 2025 | msn.comEarnings call transcript: Medexus Q3 FY2025 shows revenue growth, FDA approvalFebruary 6, 2025 | msn.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Raymond JamesFebruary 3, 2025 | markets.businessinsider.comVentum Financial Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)January 30, 2025 | markets.businessinsider.comMedexus Pharmaceuticals Launches Public Offering to Enhance Financial FlexibilityJanuary 27, 2025 | tipranks.comSee More Headlines PDDPF Stock Analysis - Frequently Asked Questions How have PDDPF shares performed this year? Medexus Pharmaceuticals' stock was trading at $2.14 at the beginning of 2025. Since then, PDDPF shares have increased by 0.0% and is now trading at $2.14. View the best growth stocks for 2025 here. How do I buy shares of Medexus Pharmaceuticals? Shares of PDDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:PDDPF CIKN/A Webwww.medexus.com Phone(514) 762-2626FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:PDDPF) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredAm I wrong for thinking this about you?The media says Trump supporters are giving up. But I know the truth: you’re the kind of American who doesn’t f...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
